167 related articles for article (PubMed ID: 36828057)
1. Denosumab salvage therapy in an 11-year-old boy with locally recurrent unresectable giant cell tumor of the lumbar spine after surgery.
Luo Y; Xiu P; Chen H; Zeng J; Song Y; Li T
Neurochirurgie; 2023 May; 69(3):101427. PubMed ID: 36828057
[TBL] [Abstract][Full Text] [Related]
2. The risk of neurological deterioration while using neoadjuvant denosumab on patients with giant cell tumor of the spine presenting with epidural disease: a meta-analysis of the literature.
Al Farii H; McChesney G; Patel SS; Rhines LD; Lewis VO; Bird JE
Spine J; 2024 Jun; 24(6):1056-1064. PubMed ID: 38301904
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcome of recurrent giant cell tumor of the extremity in the era before molecular target therapy: the Japanese Musculoskeletal Oncology Group study.
Takeuchi A; Tsuchiya H; Ishii T; Nishida Y; Abe S; Matsumine A; Kawai A; Yoshimura K; Ueda T
BMC Musculoskelet Disord; 2016 Jul; 17():306. PubMed ID: 27448567
[TBL] [Abstract][Full Text] [Related]
4. Recurrent giant cell tumour of the thoracic spine managed by total en bloc spondylectomy and denosumab therapy: a case report.
Duan PG; Sheng YH; Deng CH; Tang BY; Yao HQ
BMC Musculoskelet Disord; 2020 Feb; 21(1):105. PubMed ID: 32061254
[TBL] [Abstract][Full Text] [Related]
5. Short-term Preoperative Denosumab With Surgery in Unresectable or Recurrent Giant Cell Tumor of Bone.
Zhang RZ; Ma TX; Qi DW; Zhao M; Hu T; Zhang GC
Orthop Surg; 2019 Dec; 11(6):1101-1108. PubMed ID: 31762217
[TBL] [Abstract][Full Text] [Related]
6. A High-grade Sarcoma Arising in a Patient With Recurrent Benign Giant Cell Tumor of the Proximal Tibia While Receiving Treatment With Denosumab.
Aponte-Tinao LA; Piuzzi NS; Roitman P; Farfalli GL
Clin Orthop Relat Res; 2015 Sep; 473(9):3050-5. PubMed ID: 25758379
[TBL] [Abstract][Full Text] [Related]
7. Recurrent giant cell tumour of the maxillary sinus and pterygoid process treated with denosumab.
Rosa D; Dias RB; Salvador JC; Borges A
BMJ Case Rep; 2018 Sep; 2018():. PubMed ID: 30196254
[TBL] [Abstract][Full Text] [Related]
8. Giant cell tumor of a lumbar vertebra in a 7-year-old child: a case report.
Metkar U; Wardak Z; Katz DA; Lavelle WF
J Pediatr Orthop; 2012 Dec; 32(8):e76-80. PubMed ID: 23147636
[TBL] [Abstract][Full Text] [Related]
9. Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone.
Rutkowski P; Ferrari S; Grimer RJ; Stalley PD; Dijkstra SP; Pienkowski A; Vaz G; Wunder JS; Seeger LL; Feng A; Roberts ZJ; Bach BA
Ann Surg Oncol; 2015 Sep; 22(9):2860-8. PubMed ID: 26033180
[TBL] [Abstract][Full Text] [Related]
10. Denosumab-treated Giant Cell Tumor of Bone Exhibits Morphologic Overlap With Malignant Giant Cell Tumor of Bone.
Wojcik J; Rosenberg AE; Bredella MA; Choy E; Hornicek FJ; Nielsen GP; Deshpande V
Am J Surg Pathol; 2016 Jan; 40(1):72-80. PubMed ID: 26414220
[TBL] [Abstract][Full Text] [Related]
11. Giant cell tumor of the cervical spine: a series of 22 cases and outcomes.
Junming M; Cheng Y; Dong C; Jianru X; Xinghai Y; Quan H; Wei Z; Mesong Y; Dapeng F; Wen Y; Bin N; Lianshun J; Huimin L
Spine (Phila Pa 1976); 2008 Feb; 33(3):280-8. PubMed ID: 18303460
[TBL] [Abstract][Full Text] [Related]
12. Risks and benefits of combining denosumab and surgery in giant cell tumor of bone-a case series.
Müller DA; Beltrami G; Scoccianti G; Campanacci DA; Franchi A; Capanna R
World J Surg Oncol; 2016 Nov; 14(1):281. PubMed ID: 27809843
[TBL] [Abstract][Full Text] [Related]
13. Current management of giant-cell tumor of bone in the denosumab era.
Nagano A; Urakawa H; Tanaka K; Ozaki T
Jpn J Clin Oncol; 2022 May; 52(5):411-416. PubMed ID: 35199172
[TBL] [Abstract][Full Text] [Related]
14. Unresectable Clival Giant Cell Tumor, Tumor Control With Denosumab After Relapse: A Case Report and Systematic Review of the Literature.
Pionelli MG; Asaftei SD; Tirtei E; Campello A; Di Rosa G; Fagioli F
J Pediatr Hematol Oncol; 2022 Jul; 44(5):201-209. PubMed ID: 35537059
[TBL] [Abstract][Full Text] [Related]
15. The role of Denosumab in joint preservation for patients with giant cell tumour of bone.
Perrin DL; Visgauss JD; Wilson DA; Griffin AM; Abdul Razak AR; Ferguson PC; Wunder JS
Bone Joint J; 2021 Jan; 103-B(1):184-191. PubMed ID: 33380180
[TBL] [Abstract][Full Text] [Related]
16. [Treatment progress on giant cell tumors of bone].
Liang P
Zhongguo Gu Shang; 2018 Mar; 31(3):292-296. PubMed ID: 29600686
[TBL] [Abstract][Full Text] [Related]
17. Response to Denosumab in 2 Children With Recurrent Giant Cell Tumor of the Bone With Pulmonary Metastasis.
Reddy K; Ramirez L; Kukreja K; Venkatramani R
J Pediatr Hematol Oncol; 2021 Mar; 43(2):e215-e218. PubMed ID: 31714440
[TBL] [Abstract][Full Text] [Related]
18. Is Treatment with Denosumab Associated with Local Recurrence in Patients with Giant Cell Tumor of Bone Treated with Curettage? A Systematic Review.
Tsukamoto S; Tanaka Y; Mavrogenis AF; Kido A; Kawaguchi M; Errani C
Clin Orthop Relat Res; 2020 May; 478(5):1076-1085. PubMed ID: 31794487
[TBL] [Abstract][Full Text] [Related]
19. ASO Author Reflections: Preoperative Denosumab May Increase the Risk of Local Recurrence of Giant Cell Tumor of Bone after Curettage Surgery.
Asano N; Horiuchi K
Ann Surg Oncol; 2022 Jun; 29(6):4001. PubMed ID: 35169975
[No Abstract] [Full Text] [Related]
20. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study.
Chawla S; Blay JY; Rutkowski P; Le Cesne A; Reichardt P; Gelderblom H; Grimer RJ; Choy E; Skubitz K; Seeger L; Schuetze SM; Henshaw R; Dai T; Jandial D; Palmerini E
Lancet Oncol; 2019 Dec; 20(12):1719-1729. PubMed ID: 31704134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
